Citations

Clear

95 citation(s) found for "Diamond, M P".

Systolic time interval recordings as a measure of cardiac function in the healthy rabbit: Reference values
Long, Harry J., Diamond, Sheldon S., Burningham, Richard A., Raflo, Charles P.

Mayo Clinic

American Journal of Veterinary Research | February 6, 2025 | Volume: 43 | Issue: 8 | Pages: 1497-1499

10.2460/ajvr.1982.43.08.1497 Get It

SUMMARY Results of systolic time interval recordings obtained serially on 104 female New Zealand White rabbits were analyzed for reproducibility, variation with respect to changes in heart rate (hr), and interrelationship of the various systolic time intervals. A table of values for systolic time intervals in the healthy rabbit was constructed. The preejection period (pep), left ventricular ejection time (lvet), and pep/lvet ratio were 0.040 ± 0.008 s, 0.119 ± 0.014 s, and 0.337 ± 0.066 respectively. The major systolic time intervals, pep and lvet, varied with respect to hr according to the regression equations: pep = 0.057 − 0.000078 hr and lvet = 0.175 − 0.000251 hr. The QS2 interval, S1S2 interval and isovolumic contraction time also varied with changes in hr.
Systolic time interval recordings in rabbits with congestive cardiomyopathy induced by chronic anthracycline administration
Long, Harry J., Diamond, Sheldon S., Burningham, Richard A., Raflo, Charles P.

Mayo Clinic

American Journal of Veterinary Research | February 6, 2025 | Volume: 44 | Issue: 7 | Pages: 1375-1377

10.2460/ajvr.1983.44.07.1375 Get It

SUMMARY Systolic time interval recordings were performed serially on 104 healthy female New Zealand White rabbits and 51 rabbits with congestive heart failure (chf) induced by chronic anthracycline drug therapy. The results were analyzed and the comparisons were made with studies of systolic time interval recordings of chf in persons. In the rabbit, chf is manifested by prolongation of the isovolumic contraction time, the preejection period (pep), and by shortening of the left ventricular ejection time (lvet). The ratio of pep/lvet was a sensitive indicator of left ventricular failure, with values in excess of 0.466 reflecting significant cardiac dysfunction at the 95% confidence level. The mean pep/lvet = 0.337 ± 0.66 in healthy rabbits and pep/lvet = 0.502 ± 0.075 in rabbits with chf. The pep index increased from 0.057 ± 0.007 in healthy rabbits to 0.074 ± 0.007 in rabbits with heart failure. The lvet index decreased from 0.173 ± 0.007 in healthy rabbits to 0.166 ± 0.010 in rabbits with chf.
Characteristics of In Vivo Lesion Formation With a Temperature-Controlled Diamond-Tip Radiofrequency Ablation Catheter in the Ventricle: A Preclinical Model
Hirao, Tatsuhiko , Rettmann, Maryam E. , Schmidt, Megan , Yasin, Omar , Kowlgi, Gurukripa N. , Otsuka, Naoto , Koya, Taro , Newman, Laura K. , Packer, Douglas L. , Siontis, Konstantinos C. , Schmidt, Megan M , Yasin, Omar , Kowlgi, Narayan G

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | January 24, 2025 | Volume: 18 | Issue: 2 | Pages: No page available

10.1161/circep.124.013120 | PMID 39851050 Get It

BACKGROUND: Power-controlled radiofrequency ablation with irrigated-tip catheters has been the norm for ventricular ablation for almost 2 decades. New catheter technology has recently integrated more accurate tissue temperature sensing enabling temperature-controlled irrigated ablation. We aimed to investigate the in vivo ablation parameters and lesion formation characteristics in ventricular myocardium using a novel temperature-controlled radiofrequency catheter. METHODS: Twenty canines were divided into 3 groups: 4 noninfarcted, acute (phase I); 8 noninfarcted, chronic (phase II); and 8 infarcted, chronic (phase III). Lesions were delivered with a temperature-controlled radiofrequency system utilizing a chemical vapor deposit diamond for efficient thermal diffusivity. In phase I, 17 ablation settings were tested (temperature set points, 50/60/70 °C; ablation duration, 15/30/60/90/120 s; and power limit, 30/50 W). Four and one of these sets of parameters were further tested in phases II and III, respectively. Lesions were assessed by ex vivo contrast-enhanced magnetic resonance imaging and gross pathology 5 weeks after ablation in phases II/III. RESULTS: Across all phases, 111 ablation lesions were delivered. Ablation with the power limit of 50 W, the temperature set point of 60 °C, and the duration of 60 s produced significantly larger and deeper lesions (mean, 569.2 mm 3 ; mean maximal depth, 9.8 mm) compared with 50 W/60 °C/30 s (mean, 340.4 mm 3 ; mean maximal depth, 8.3 mm) and 50 W/50 °C/60 s (mean, 227 mm 3 ; mean maximal depth, 6.9 mm), with P <0.05 for all pairwise comparisons. Ablation of infarcted myocardium in phase III (50 W/60 °C/30 s) resulted in smaller impedance and bipolar electrogram amplitude changes and lesion size compared with ablation in normal myocardium with the same settings. No steam pop, myocardial perforation, or char formation was observed in any of the 111 ablations across all phases. CONCLUSIONS: In vivo radiofrequency ablation in a canine model with a diamond-tip temperature-controlled catheter using a temperature set point of 60 °C and a power limit of 50 W created large lesions without steam pop risk in both normal and infarcted ventricular myocardia.
Teaching Radiology: An Evidence-based Overview for Radiology Residents
Bentley, H. Brian , Rouzrokh, Pouria , Pishgar, Farhad , Clarke, Jamie E. , Santo, Irene Dixe de Oliveira , Bentley, Helena , Dixe de Oliveira Santo, Irene , Rouzrokh, Pouria

Mayo Clinic

RadioGraphics | January 21, 2025 | Volume: 45 | Issue: 2 | Pages: No page available

10.1148/rg.240181 | PMID 41543879 Get It

Approach to the Patient: From Endocrinopathy to the Diagnosis of a Histiocytic Disorder
Makras, Polyzois , Erickson, Dana , Davidge‐Pitts, Caroline , Allen, Carl E. , Abeykoon, Jithma P. , Siwakoti, Krishmita, Ravindran, Aishwarya , Gruber, Lucinda , Goyal, Gaurav , Ravindran, Aishwarya , Goyal, Guarav , Makras, Polyzois , Allen, Carl E , Diamond, Eli L. , McClain, Kenneth L. , Go, Ronald S. , Sotoudeh, Houman

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 17, 2024 | Volume: 110 | Issue: 6 | Pages: 1756-1766

10.1210/clinem/dgae827 | PMID 39699236 Get It

Abstract Endocrinopathies are frequently the initial presentation of histiocytic neoplasms, which are rare hematologic disorders affecting multiple organ systems. Langerhans cell histiocytosis and Erdheim–Chester disease are 2 such disorders known to infiltrate the hypothalamus and/or pituitary gland, leading to arginine vasopressin deficiency (AVP-D) and anterior pituitary dysfunction (APD) in 20% to 30% of cases, often as the first manifestation. Conversely, histiocytic disorders account for a notable proportion (10-15%) of all pituitary stalk lesions. The diagnosis of histiocytoses is often delayed in such cases due to the nonspecific presentation of endocrinopathies and pituitary involvement. Consequently, endocrinologists are at the frontline and uniquely positioned to achieve early diagnosis by recognizing the varied nonendocrine features of these disorders. This article provides an overview of the endocrine manifestations of histiocytic disorders and presents a simplified algorithm to guide the diagnostic workup in cases presenting with “idiopathic” AVP-D or APD. Such cases should be evaluated for histiocytic neoplasms with additional imaging studies and biopsies of suspected disease sites. If no disease site beyond the pituitary is identified, the risks and benefits of a pituitary stalk lesion biopsy must be carefully considered. While treatments of histiocytic neoplasms are highly efficacious, endocrinopathies are considered permanent and require long-term hormone replacement. It remains unclear whether early diagnosis and novel targeted therapies can reverse these endocrine disorders. Therefore, the role of the endocrinologist role is critical in the diagnosis and management of these rare diseases.
Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
Poos, Alexandra M. , Lee, Holly , Wiedmeier, Julia E. , Otteson, Gregory E., Tang, Hongwei , Fröhling, Stefan , Papadimitriou, Marios , Jelinek, Tomas, Bergsagel, P. Leif , Kumar, Shaji , Weinhold, Niels , Wiedmeier-Nutor, Julia E , Diamond, Benjamin , Baughn, Linda B. , Poorebrahim, Mansour , Kaddoura, Marcella , Durante, Michael , Jevremović, Dragan , Tang, Hongwei, Ziccheddu, Bachisio , Landgren, Ola , Neri, Paola , Bergsagel, P. Leif , Braggio, Esteban , Raab, Marc S. , Fonseca, Rafaël , Bahlis, Nizar Jacques , Maura, Francesco

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 592-592

10.1182/blood-2024-201056 Get It

Introduction Monoclonal antibodies (MoAbs) directed against CD38 are a mainstay in multiple myeloma (MM). Downregulation of CD38 expression is a resistance mechanism of antigenic escape, however, cell surface expression may return. While this tumor cell plasticity is likely driven by epigenetic mechanisms, it is unknown if MM cells can develop permanent resistance to anti-CD38 MoAb by acquiring genomic events leading to biallelic disruption of CD38 thus precluding re-treatment. Here, we report biallelic loss of CD38 as a recurrent mechanism of resistance, often via convergent evolution where distinct subclones are advantaged towards the same selective pressure. Methods We interrogated two sets of patients (Mayo Clinic; n = 31, Calgary University; n =19) with relapse following anti-CD38 MoAbs. Two additional cases of interest were selected from Heidelberg University. Whole genome sequencing (WGS, 60-100x) or whole exome sequencing (WXS), flow cytometry (flow), and bulk RNAseq were used to validate the effect of genomic events on CD38. Missense mutations predicted to affect CD38 MoAb binding were validated with site-directed mutagenesis of a CD38 plasmid, transduction into K562 MM cells, and CD38 MoAb binding assays. Results The prevalence of biallelic inactivation of CD38 at anti-CD38 MoAb relapse was 6% (3/50). An additional selected biallelic event was noted in the Heidelberg set. Each case is described in detail: MM-19 (Calgary) received daratumumab (Dara), lenalidomide, and dexamethasone (Dex), and then had a second exposure to Dara, following relapse. At this second relapse, WGS was performed on two independent extramedullary disease localizations in the liver. Both samples had unique, large deletions (&gt;3 Mb) on chromosome 4 coupled with additional unique focal deletions involving CD38. Flow confirmed the presence of CD138+/CD38- plasma cell populations in both sites. A second case of convergent evolution was seen in a patient (Mayo) after seventh-line Dara/Len/Dex. WGS revealed a common deletion encompassing CD38. On the remaining allele, one subclone had a structural variation-mediated loss of CD38(cancer cell fraction; CCF 40%) while another harbored an L153H missense mutation (CCF 60%). Flow confirmed presence of two CD138+ clones; one with diminished CD38 expression. L153H was functionally validated to abrogate Dara binding, while maintaining CD38 expression. The third sample was collected after fifth-line Dara and sixth-line Dara/Bortezomib/Dex (Heidelberg) and represents another case of convergent evolution with a common loss of chromosome 4 and two subclones detected by WGS (P98Lfs*12, CCF 39% resulting in biallelic inactivation; R140G, CCF 61%). Bulk RNAseq revealed, in comparison to NDMM from CoMMpass, CD38 expression below the first decile. Notably, the R140G variant reduced binding affinity to Dara but not to Isatuximab (Isa). A fourth case (Mayo) relapsing after 6 months of Dara-based therapy similarly had a focal deletion of CD38 with an L18Sfs*16 frameshift deletion on the remaining allele associated with a 4.35-fold reduction in CD38 expression by RNAseq compared to pre-treatment. Interestingly, in 3/4 cases the CD38-negative clone emerged after a second exposure to anti-CD38 MoAb, suggesting emergence with the first exposure and then selection during the second. One other monoallelic event (C275Y; Heidelberg) was detected post-Isa. Copy number of the alternate allele is not known given targeted sequencing methodology, but the variant was seen to reduce binding affinity to both Dara and Isa. The prevalence of monoallelic loss of CD38 in newly diagnosed MM from MMRF CoMMpass was 7% (50/701) and two patients had mutations in CD38, but there were no cases of biallelic loss suggesting these events are driven by treatment pressure. Conclusion Distinction of the mode of CD38 loss is valuable for predicting outcome of re-challenge to anti-CD38 MoAbs. We see here an estimated 5-10% of anti-CD38 MoAb relapses are characterized by genomic antigen escape. Results here are in line with antigen escape to BCMA- and GPRC5D-directed immunotherapies (Lee et al, Nat Med 2023), suggesting that acquired antigen escape resulting from prolonged exposure to the selective pressures of immunotherapy is a recurrent mechanism of resistance in MM. Moreover, in select cases, non-overlapping resistance mutations provide rationale for switching agents at second exposure.
Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma
Bhatnagar, Vishal , Copley, Devin B, Diamond, Matthew, Faust, Louis , Power, Brad , Ritchie, Jessica , Ruddy, Kathryn J. , Tarver, Michelle E. , Torre, La, Gross, Cary P. , Thanarajasingam, Gita , Paludo, Jonas , Dueck, Amylou C. , Brown, Abbie Y, Cathcart-Rake, Elizabeth , Diamond, Matthew, Fiero, Mallorie H. , Huntington, Scott F. , Jeffery, Molly Moore , Jones, Lee W. , Noble, Brie N. , Ross, Joseph S. , Mougalian, Sarah S. , Torre, Lisa M, Wood, William A. , Kluetz, Paul Gustav

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 387-387

10.1182/blood-2024-194607 Get It

Background: Physical function (PF) is an important outcome that can inform cancer treatment tolerability from a clinical and regulatory perspective. PF can be assessed through different modalities: patient-reported (PRO), clinician-reported (ClinRo), performance tests (PerfO), and digital sensors (wearables). No standard approach for PF measurement has been defined, and each modality bears unique implementation challenges. The Integrating 4 Measures to Assess Physical Function study (In4M, NCT05214144) characterized the performance of these PF modalities in patients receiving cytotoxic chemotherapy, with a goal of guiding an assessment strategy in future cancer trials. Here we present feasibility results of the In4M study in patients with lymphoma. Methods: In4M is a prospective observational study with longitudinal PF assessment of PROs, ClinRo, PerfO, and wearable sensor data for over 9 months in patients initiating chemotherapy for lymphoma or breast cancer at Mayo Clinic and Yale University. Patient-reported PF was assessed using several validated ePRO instruments, ClinRo utilized clinician-reported Eastern Cooperative Oncology Group (ECOG) performance status, PerfO was measured via 6-minute walk test (6MWT), and digital sensor data was obtained from a wearable (Fitbit) provided to all participants. We evaluated the feasibility of implementing these PF modalities through compliance outcomes and a study-specific exit survey. Descriptive statistics included medians and interquartile ranges (IQR) for continuous variables and frequencies for categorical variables. We used a mixed model to estimate mean number of Fitbit compliant days per week. Results: Among 66 patients with lymphoma in the study (median age was 57 years; 52% were male), 90% self-reported as White, 4.9% as Black, 1.6% as Asian, 1.6% as American Indian or Alaska Native, and 1.6% as multiple races. Ethnicity was reported as non-Hispanic/Latino by 93% of patients. Education status was reported as more than high school by 92% of patients, and 49% reported full-time employment at time of enrollment. The overall ePROs completion rate was 80.7% for the entire study period. Baseline ePRO completion rate was 93.9%. Completion rate while undergoing chemotherapy was 91.3% and 75.4% in the post-treatment follow-up. The median time to complete ePROs was 4.1 minutes (IQR 2.8-5.9), ranging from 3.1 minutes for surveys with 37 questions to 5.6 minutes for surveys with 55 questions (survey length varied by timepoint). The baseline 6MWT was completed by 91% of patients. The most common reasons for not completing the baseline 6MWT were: patient refusal (50%, 3/6), patient not physically present (33%, 2/6), and unable to complete due to fatigue (17%, 1/6). The 3-month 6MWT was completed by 66% (40/61) of patients, with the most common reasons for missingness being: patient not physically present (38%, 8/21) and unable to complete due to fatigue (14%, 3/21). When considering the days when Fitbit was used, the median wear time was 21.3 hours (IQR 18.9-22.5) per day. The proportion of compliant days (&gt;10 hours of wear time during waking hours) was 53% (IQR 20-84). The median of participants' average compliant days per week was 5.4 (IQR 4.3-6.1) days/week after enrollment, with a slight downward trend over time (-0.017 compliant days per week [95% CI: -0.021, -0.012, p &lt;0.001] over each consecutive week in the study). The exit survey was completed by 39 (59%) patients. Most participants (85%) indicated they did not find the ePRO surveys burdensome to complete. Using the Fitbit (charging and syncing) was found to be manageable by most patients (87% and 84%, respectively). 60.8% of patients did not find the wearable bothersome to use, while the main themes reported by the remaining patients were related to the operation of the wearable itself (functions, small text size, forgetting login information) or discomfort (band material, wearing at night). Conclusion: Multi-modal assessment of PF with PRO, ClinRo, PerfO and wearable sensor data in patients with lymphoma undergoing treatment is feasible. Designing lymphoma therapeutic trials that incorporate at least one PF assessment modality, or assessment with a parsimonious combination of modalities, is achievable and may yield valuable insights into treatment tolerability for clinical and regulatory purposes.
Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
Blaney, Patrick , Papadimitriou, Marios , Zhang, Di , Cirrincione, Anthony , Poos, Alexandra M. , Korde, Neha , Rasche, Leo , Mai, Elias K., Weinhold, Niels , Brown, Elizabeth , Bergsagel, Leif, Blaney, Patrick , Maclachlan, Kylee , Mikulášová, Aneta , Gagler, Dylan , Braunstein, Marc , Lahoud, Oscar , Kaminetzky, David , Wang, Yubao , Liu, Sanxiong , Ziccheddu, Bachisio , Kaddoura, Marcella , Chojnacka, Monika , Diamond, Benjamin , Lesokhin, Alexander M. , Usmani, Saad Z. , Mai, Elias K., Raab, Marc S. , Robine, Nicolas , Bergsagel, P. Leif , Walker, Brian A. , Landgren, Ola , Maura, Francesco , Davies, Faith E. , Morgan, Gareth J.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4655-4655

10.1182/blood-2024-211012 Get It

Introduction The pathogenic role of somatic non-coding (nc) single nucleotide variants (SNVs) is underexplored in multiple myeloma (MM) and additional characterization of these regions has the potential to provide significant new insights into disease progression. To investigate the role of ncSNVs and their relationship with MM pathogenesis, we have characterized a novel series of WGS from 294 cases of MGUS, SMM, and MM using computational tools optimized to identify functional driver SNVs in these regions. We hypothesize the ncSNVs that co-localize to sites of super-enhancers (SEs) active in plasma cells (PC) are sites of high functional impact SNVs and these mutations lead to the dysregulated expression of genes that should be silent at the terminally differentiated stage of PCs, providing a selective advantage that shapes the fitness of the MM genomic landscape. Methods We analyzed 294 high-coverage matched tumor/normal pairs (80x tumor and 40x normal) derived from 21 MGUS, 86 SMM, 167 NDMM and 40 RRMM. In addition to previously sequenced samples, newly sequenced patients were obtained from NYU Langone Health, Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham and University of Miami following IRB-approved informed consent. DNA was extracted from CD138+ purified bone marrow plasma cells using standard approaches. We used the MGP1000 (https://github.com/pblaney/mgp1000) to process sequencing data which employs a union-consensus mechanism for determining the final set of variants. We collected enhancer elements (E/SEs) active in GC B-cells, ABC-DLBCL and GBC-DLBCL (Bal, et al. Nature, 2022) and PC specific E/SEs (Loven, et al. Cell 2013). FunSeq2 was used to score ncSNVs. GRAM was used to predict how variants alter TF binding and gene expression in a subset of 6 cases with paired WGS in our series and will expand this analysis on a validation set of 263 NDMM and 93 RRMM cases from University-Hospital Heidelberg enrolled in the GMMG-HD6 clinical trial. Results We identified 1,952,232 high-quality SNVs with 18,199 (0.93%) accumulating in 280 focal sites we termed “mutationally enriched regions” or MERs. To discern SNVs in MERs with the highest potential for imparting a selective advantage, we clustered mutations based on the density of FunSeq2 impact scores which uses reference data contexts on sequence conservation, modification of transcription factor (TF) binding, and gene linkage to regulatory elements and network hubs from pan-cancer studies. We show that MERs are enriched for ncSNVs with high impact scores (mean=2.57) compared to random similarly-sized regions of the genome (Fisher's exact test P&lt;9.7e-12, OR=10.10 [3.88-37.40]). The high impact ncSNVs (hi-ncSNVs) in MERs (n=220) account for 8.09% of all hi-ncSNVs and are present in 46.3% of cases (136/294) with some patients having up to 7. The proportion of cases carrying a MER hi-ncSNVs was similar across disease stages (MGUS=42.9%, SMM=46.5%, MM=40.7%, and RR=47.5%). Analysis of the VAF of MER hi-ncSNVs shows a minor shift towards more clonal versus subclonal mutations (53.6% vs 46.4% VAF&gt;=0.25) suggesting some high impact mutations are acquired in the GC but additional hi-ncSNV are acquired later in PC development, providing evidence that hi-ncSNVs accumulate in MERs throughout disease progression. We mapped these hi-ncSNVs to associated genes then intersected the loci with E/SEs active in GCBs and PCs to determine their functional context. This approach identified 12 genes affected by hi-ncSNVs including the previously identified nc-drivers NEAT1, MIR142, ZCCHC7, and IGLL5 as well as the PC differentiation genes IRF8, BACH2, proliferation genes RHOH, SPRED2, known coding MM drivers CCND1, ZFP36L1, and chr1q genes BTG2 and CROCC. We predicted the effect of ncSNVs on expression through modulation of TF binding at this set of putative nc drivers in MM and identified a trend towards increase in expression of SPRED2, CCND1, NEAT1, and IGLL5 compared to non-mutated cases (P=0.089). We will present data on the validation of this set of genes on a larger set of data derived from the Heidelberg group. Conclusions We identified a set of 12 putative nc driver genes in MM that modify expression and have the potential to significantly alter the pathogenesis of MM by providing a selective survival advantage. We will present the impact of these by clinical stage and on outcome.
S218 Characterizing Individuals With Recurrent Acute Pancreatitis and Exocrine Pancreatic Insufficiency: Findings From the PACT-CP Registry
Diamond, Jane A., Alkaade, Samer, Twal, Janine, Pack, Jennifer, Diamond, Jane A., Yachimski, Patrick , Hernandez‐Barco, Yasmin G.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S159-S160

10.14309/01.ajg.0001029240.67546.ea Get It

Repetitive Head Impacts and Perivascular Space Volume in Former American Football Players
Jung, Leonard , Wiegand, Tim L. T. , Tuz‐Zahra, Fatima , Iliff, Jeffrey J. , Piantino, Juan , Arciniega, Hector , Kim, Cara L., Pankatz, Lara, Lin, Alexander , Alosco, Michael L. , Daneshvar, Daniel H. , Pasternak, Ofer , Coleman, Michael J. , Bernick, Charles , Balcer, Laura J. , Reiman, Eric M. , Shenton, Martha E., Protas, Hillary , Boker, Conni, Kowall, Neil W. , Otis, James , Weller, Jason , Simkin, Irene, Andino, Alondra, Diamond, Courtney , Fagle, Tessa, Haller, Olivia, Hung, Tennyson, Gullotti, Nicole, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen , Nanna, Mary, Platt, Taylor, Pulukuri, Sury, Rica, Fiona, Sestak, Madison, Annis, Douglas S. , Dixon, Dianne B., Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Martin, Brett, Palmisano, Joseph , Pine, Brittany, Fitzsimmons, Jennifer, Breedlove, Katherine M. , Coello, Eduardo , Liao, Hujiun, Rizzoni, Elizabeth, Schultz, Vivian , Silva, Annelise, Vessey, Brynn, Banks, Sarah J. , Ritter, Aaron, Sabbagh, Marwan N. , Cruz, Raelynn de la, Durant, Jan, Golceker, Moragn, Harmon, Nicolette, Kaylegian, Kaeson, Long, Rachelle, Nance, Christin, Sandoval, Priscilla, Serrano, Andrew, Falk, Bryce W., Duffy, Amy, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Kirov, Ivian, Marmar, Charles R. , Hasanaj, Lisene, Serrano, Liliana , Al-Kharafi, Alhassan, George, Allan , Martin, Sammie, Runge, William, Peskind, Elaine R. , Colasurdo, Elizabeth A. , Marcus, Daniel S. , Gurney, Jenny , Johnson, Keith A. , Greenwald, Richard M., Shenton, Martha E. , Daneshvar, Daniel H , Shenton, Martha E , Tripodis, Yorghos , Bouix, Sylvain , Mez, Jesse , Sepehrband, Farshid , Rathi, Yogesh , Adler, Charles H. , Cummings, Jeffrey L. , Stern, Robert A. , Koerte, Inga K , Su, Yi , Chen, Kewei , Boker, Connie, Au, Rhoda , Cantu, Robert C. , Farrer, Lindsay A. , Helm, Robert H. , Mercier, Gustavo , Conneely, Shannon E. , Diamond, Courtney, Pulukuri, Surya Vamsi , McClean, Michael D , Annis, Douglas, Chaisson, Christine E. , Finney, Carolyn, Lü, Jun , Ojo, Emmanuel, Ramachandran, Janani , Bonke, Elena M. , Breedlove, Katherine , Miller, Jason Rafe , II, Robert W. Turner , Marek, Kenneth , Dodick, David W. , Geda, Yonas E. , Wethe, Jennifer V. , Falk, Bryce, Montague, Michelle, Barr, William , Goldberg, Judith D. , Wısnıewskı, Thomas , Lui, Yvonne W. , George, Allan, Riley, Edward P.

Mayo Clinic

JAMA Network Open | August 26, 2024 | Volume: 7 | Issue: 8 | Pages: e2428687

10.1001/jamanetworkopen.2024.28687 | PMID 39186275 Get It

ImportanceExposure to repetitive head impacts (RHI) is associated with increased risk for neurodegeneration. Accumulation of toxic proteins due to impaired brain clearance is suspected to play a role.ObjectiveTo investigate whether perivascular space (PVS) volume is associated with lifetime exposure to RHI in individuals at risk for RHI-associated neurodegeneration.Design, Setting, and ParticipantsThis cross-sectional study was part of the Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy (DIAGNOSE CTE) Research Project, a 7-year multicenter study consisting of 4 US study sites. Data were collected from September 2016 to February 2020 and analyses were performed between May 2021 and October 2023. After controlling for magnetic resonance image (MRI) and processing quality, former American football players and unexposed asymptomatic control participants were included in analyses.ExposurePrior exposure to RHI while participating in American football was estimated using the 3 cumulative head impact indices (CHII-G, linear acceleration; CHII-R, rotational acceleration; and CHII, number of head impacts).Main Outcomes and MeasuresIndividual PVS volume was calculated in the white matter of structural MRI. Cognitive impairment was based on neuropsychological assessment. Linear regression models were used to assess associations of PVS volume with neuropsychological assessments in former American football players. All analyses were adjusted for confounders associated with PVS volume.ResultsAnalyses included 224 participants (median [IQR] age, 57 [51-65] years), with 170 male former football players (114 former professional athletes, 56 former collegiate athletes) and 54 male unexposed control participants. Former football players had larger PVS volume compared with the unexposed group (mean difference, 0.28 [95% CI, 0.00-0.56]; P = .05). Within the football group, PVS volume was associated with higher CHII-R (β = 2.71 × 10−8 [95% CI, 0.50 × 10−8 to 4.93 × 10−8]; P = .03) and CHII-G (β = 2.24 × 10−6 [95% CI, 0.35 × 10−6 to 4.13 × 10−6]; P = .03). Larger PVS volume was also associated with worse performance on cognitive functioning in former American football players (β = −0.74 [95% CI, −1.35 to −0.13]; P = .04).Conclusions and RelevanceThese findings suggest that impaired perivascular brain clearance, as indicated by larger PVS volume, may contribute to the association observed between RHI exposure and neurodegeneration.